
1. Am J Trop Med Hyg. 2017 Jul;97(1):222-224. doi: 10.4269/ajtmh.16-0889.

Molecular Epidemiology of Malaria in Cameroon and Côte d'Ivoire. XXXI. Kelch 13
Propeller Sequences in Plasmodium falciparum Isolates before and after
Implementation of Artemisinin-Based Combination Therapy.

Djaman JA(1)(2), Olefongo D(1)(2), Ako AB(1)(2), Roman J(3)(4), Ngane VF(5),
Basco LK(6)(5), Tahar R(4)(5)(3).

Author information: 
(1)Département de Parasitologie-Mycologie, Institut Pasteur de Côte d'Ivoire,
Abidjan, Côte d'Ivoire.
(2)Laboratoire de Pharmacodynamie Biochimique, UFR Biosciences, Université Félix 
Houphouët-Boigny, Abidjan, Côte d'Ivoire.
(3)PRES Sorbonne Paris Cité, Université Paris Descartes Faculté de Pharmacie,
Paris, France.
(4)Unité Mixte de la Recherche 216, Mère et Enfant Face aux Infections
Tropicales, Institut de Recherche pour le Développement (IRD), Unité de Formation
et de Recherche (UFR) de Pharmacie, Université Paris Descartes, Paris, France.
(5)Organisation de Coordination pour la lutte contre les Endémies en Afrique
Centrale (OCEAC), Yaoundé, Cameroon.
(6)Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes
(URMITE), Aix-Marseille Université, Institut Hospitalo-Universitaire Méditerranée
Infection, Marseille, France.

Artemisinin-resistant malaria has not been reported from Africa, but resistance
can possibly spread from Asia or arise independently in Africa. The emergence of 
artemisinin resistance in Africa can be monitored by molecular assay of Kelch 13 
(K13) propeller sequences. A total of 251 archived DNA samples of Plasmodium
falciparum isolates collected in 2002, 2003, and 2006 in Yaounde, Cameroon, and
47 samples collected in 2006 and 2013 in Abidjan, Côte d'Ivoire, were analyzed
for K13-propeller sequence polymorphism. Only one isolate carried a mutant
K13-propeller allele (E602D). None of the isolates carried the key mutant alleles
(Y493H, R539T, I543T, and C580Y) associated with artemisinin resistance in
Cambodia. The presence of the mutant allele was not correlated with in vitro
response to dihydroartemisinin determined by the classical hypoxanthine
incorporation assay. There was no evidence of K13 mutations associated with
artemisinin resistance before and soon after the introduction of
artemisinin-based combination therapies in Cameroon and Côte d'Ivoire.

DOI: 10.4269/ajtmh.16-0889 
PMCID: PMC5508902
PMID: 28719312  [Indexed for MEDLINE]

